Holen Sie sich die Stockscreener-App
4.47
0.67%
-0.03
Handel nachbörslich:
4.46
-0.010
-0.22%
Schlusskurs vom Vortag:
$4.50
Offen:
$4.5
24-Stunden-Volumen:
344.88K
Relative Volume:
0.12
Marktkapitalisierung:
$56.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.54M
KGV:
-2.8839
EPS:
-1.55
Netto-Cashflow:
$-18.30M
1W Leistung:
-3.25%
1M Leistung:
-29.50%
6M Leistung:
+616.46%
1J Leistung:
+1,001%
1-Tages-Spanne:
$4.40
$4.57
1-Wochen-Bereich:
$4.38
$4.72
52-Wochen-Spanne:
$0.202
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Vergleichen Sie UNCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.47 | 58.99M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Guggenheim | Buy |
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc.UNCY - WV News
Is Unicycive Therapeutics Inc. a good long term investmentTriple-digit wealth increases - jammulinksnews.com
Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth? - Yahoo Finance
Unicycive Therapeutics Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com
What analysts say about Unicycive Therapeutics Inc. stockExceptional market performance - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Best Stocks for a Post COVID Recovery in India Financial Expert RecommendationsFree Stock Market Trend Analysis - PrintWeekIndia
What analysts say about Palladyne AI Corp. stockRapid growth trajectories - jammulinksnews.com
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
What drives Unicycive Therapeutics Inc. stock priceExtraordinary earning power - jammulinksnews.com
Published on: 2025-07-18 04:29:16 - Newser
Why Unicycive Therapeutics Inc. stock is on top investor watchlistsDaily Top Gainers - Newser
Why Unicycive Therapeutics Inc. stock attracts strong analyst attentionFast Moving Stock Alerts - Newser
How Unicycive Therapeutics Inc. stock performs during market volatilityReal Chart Play - Newser
What makes Unicycive Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
Transcript : Unicycive Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 11 - MarketScreener
Pomerantz LLP Investigates Unicycive Therapeutics Securities Fraud Claims. - AInvest
Unicycive Regains Nasdaq Compliance After Stock Split - The Globe and Mail
Unicycive regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Unicycive regains Nasdaq compliance after reverse stock split - Investing.com
Unicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price Recovery - Quiver Quantitative
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Unicycive Successfully Maintains Nasdaq Listing Following 1:10 Reverse Stock Split - Stock Titan
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Unicycive Therapeutics to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference - Nasdaq
Clinical-Stage Kidney Disease Biotech Unicycive Reveals Latest Therapeutic Progress at Major Healthcare Conference - Stock Titan
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Unicycive Therapeutics - The Pharma Letter
Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN
Ongoing Unicycive Therapeutics, Inc. (UNCY) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Ongoing Securities Investigation Into Unicycive Therapeutics, Inc. (UNCY)Contact Levi & Korsinsky - ACCESS Newswire
Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com India
Unicycive hit with CRL on oxylanthanum carbonate NDA - The Pharma Letter
Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - FinancialContent
H.C. Wainwright keeps Buy on Unicycive Therapeutics , says CRL ‘anticipated’ - TipRanks
Unicycive stock falls after FDA issues Complete Response Letter By Investing.com - Investing.com Nigeria
Unicycive stock falls after FDA issues Complete Response Letter - Investing.com Australia
Pre-market Movers: BBLG, INMB, NAOV, AEMD... - RTTNews
Why Did Unicycive Plunge 13.25% in Pre-Market Trading? - AInvest
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):